LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study
Kohei Shitara(National Cancer Center Hospital East), Sun Young Rha(Yonsei University Health System), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Takashi Oshima(Kanagawa Prefectural Hospital Organization), Nina Karaseva(City Clinical Oncology Center), M. A. Osipov(Leningrad Regional Cancer Center), Hisateru Yasui(Kobe City Medical Center General Hospital), Hiroshi Yabusaki(Niigata Cancer Center Hospital), S. G. Afanasyev, Park Yk(Chonnam National University Hwasun Hospital), S-E. Al-Batran(Goethe University Frankfurt), Takaki Yoshikawa(Tokyo National Hospital), P.E. Yanez Weber(Universidad de La Frontera), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Sara Lonardi(Istituto Oncologico Veneto), Xuemin Fang(Merck & Co., Inc., Rahway, NJ, USA (United States)), C-S. Shih(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Y-J. Bang(Seoul National University)
Cited by 34Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis